C3N-02143
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- ANGIOGENESIS+0.360
- COAGULATION+0.340
- CHOLESTEROL_HOMEOSTASIS+0.300
- KRAS_SIGNALING_DN+0.260
- GLYCOLYSIS+0.190
- NOTCH_SIGNALING+0.190
- KRAS_SIGNALING_UP+0.180
- COMPLEMENT+0.170
- SPERMATOGENESIS+0.170
Top 10 suppressed
- MYC_TARGETS_V2-0.550
- MYC_TARGETS_V1-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.400
- OXIDATIVE_PHOSPHORYLATION-0.370
- PROTEIN_SECRETION-0.300
- ADIPOGENESIS-0.280
- DNA_REPAIR-0.250
- TGF_BETA_SIGNALING-0.250
- PI3K_AKT_MTOR_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG686 | — | — | 0.774 |
| 2 | SRR1467212 | GTEX | — | 0.756 |
| 3 | R216 | — | — | 0.752 |
| 4 | MNG934 | — | — | 0.750 |
| 5 | SRR1516036 | — | — | 0.745 |
| 6 | SRR1325964 | GTEX | — | 0.742 |
| 7 | BS_YE1MAQYJ | EPN | EPN Tumor | 0.737 |
| 8 | R396 | — | — | 0.730 |
| 9 | BS_A7Q8G0Y1 | Diffuse intrinsic pontine glioma | — | 0.729 |
| 10 | MDT-AP-0317 | Med | Medulloblastoma | 0.724 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |